The role of zoledronic acid in the management of osteoporosis

Clinical Rheumatology

Volumn 29, Issue 10, 2010, Pages 1079-1084

  Maricic, Michael ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Compliance; Glucocorticoid induced osteoporosis; Intravenous bisphosphonates; Male osteoporosis; Osteoporosis; Postmenopausal osteoporosis; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

BONE DENSITY; FEMALE; HUMAN; MALE; OSTEOPOROSIS; REVIEW;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MALE; OSTEOPOROSIS;

EID: 79952113554     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-010-1486-3     Document Type: Review

References (20)

1. Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645-1652
2. Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD (2007) Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 24:37-55
3. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022
4. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM et al (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209-216
5. Osterberg L, Blaschke T (2005) Adherence to medications. N Engl J Med 353:487-497
6. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965-968
7. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008
8. Dunford JF, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD et al (2001) Structure-Activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235-242
9. Green JR, Rogers MJ (2002) Pharmacological profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 55:210-224
10. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822
11. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809
12. Reid DM, Devogelaer J-P, Saag K, Roux C, Lau C-S, Reginster JY et al (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy randomised controlled trial. Lancet 373:1253-1263
13. Orwoll E, Miller P, Adachi J, Brown J, Adler R, Kendler D et al (2009) Once-yearly I.V. zoledronic acid 5 mg versus weekly oral alendronate 70 mg in men with osteoporosis. Presented at: 91st Annual Meeting of the Endocrine Society (ENDO); June 10-13, Washington DC, USA
14. McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou C-L (2009) Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass. Obstet Gynecol 114:999-1007
15. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661
16. McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A et al (2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122-128
17. Reclast [package insert] (2008) East Hanover, NJ: Novartis Pharmaceuticals Corporation
18. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D et al (2007) Bisphosphonate-Associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-1491
19. Felsenberg D, Hoffmeister B, Amling M, Mundlos S, Seibel MJ, Fratzl P (2006) Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Deutsches Ärzteblatt 103:3078-3081
20. Sambrook P, Olver I, Goss A (2006) Bisphosphonates and osteonecrosis of the jaw. Aust Fam Phys 35:801-803